Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Benda Pharmaceutical has announced that its Jiangling plant has received approval from the State Food and Drug Administration to reinitiate production of its primary product line.
Subscribe to our email newsletter
This was the last step necessary for Jiangling to be eligible for Good Manufacturing Practices (GMP) certification, a standard required in China to produce pharmaceuticals or their ingredients.
Jiangling originally closed in July 2004 to complete renovations necessary to secure GMP certification. Jiangling primary products, for which it has now received production approval, are active pharmaceutical ingredients (API). Jiangling is now eligible for GMP certification and will begin API production immediately upon certification receipt.